The development and Reform Commission cut down drug prices again, and foreign drugs accounted for 80%

From caijing.com.cn on August 5, August 8, 2011, the national development and Reform Commission issued a notice that it decided to reduce the maximum retail price of some hormones, endocrine and nervous system drugs from September 1, involving 82 varieties and more than 400 dosage forms, with an average price reduction of 14% With regard to the impact of the national development and Reform Commission's price reduction policy on the pharmaceutical industry, Jiang Guangce, a leisurely investment partner and medical fund economy, believes that from the perspective of the price reduction range, and the types and specifications of the price reduction products, the price reduction has little impact on the relevant enterprises On August 4, the latest "management measures for clinical application of antimicrobial drugs (Draft for comments)" issued by the Ministry of Health gave up the issuance of a unified national catalogue of antimicrobial drug use, which has reflected the policy characteristics of relaxing administrative control considering local differences and enterprises' bearing capacity From the perspective of the price reduction range of products involved in this policy, the types and specifications of the price reduction products, it is far lower than the previous one In the future, there is very limited space for continued price reduction of pharmaceutical products It is expected that the drug price reduction policy will be completed by the end of this year The last large-scale reduction of the maximum retail price of drugs by the development and Reform Commission was in March 2011, with a total of 162 varieties reduced, and the maximum retail price of nearly 1300 dosage forms of drugs (mainly antibiotics and circulating system drugs used to treat infections and cardiovascular diseases), with an average decrease of 21% of the regulated price before the adjustment In the drug pricing part alone, the enterprises involved in the price adjustment policy are mainly foreign-funded, including 28 enterprises including Pfizer (NYSE: PFE), Wyeth Pharmaceutical (NYSE: Wye), GlaxoSmithKline (NYSE: GSK), Xi'an Janssen, etc There are only 8 domestic enterprises involved, including Qianhong Pharmaceutical (002550 SZ), Taiji Group (600129 SH), Lizhu pharmaceutical B (200513), Shuanghe Pharmaceutical (600062 Sh ）Its holding subsidiaries include Beijing Wanhui Shuanghe Pharmaceutical Co., Ltd., Tianjin Huajin pharmaceutical factory, Wuhan Aimin Pharmaceutical Co., Ltd., Shandong LVYE Pharmaceutical Co., Ltd and Xiangbei Wellman Pharmaceutical Co., Ltd In a telephone interview, Zheng Fenglin, a representative of Qianhong pharmaceutical securities, told reporters that the NDRC's price reduction policy had limited impact on the company as a whole The company's exclusive pricing product, pancreatic kininogenase, has a small reduction in the maximum price limit The company's products are directly sold to hospitals through sales companies, with simple circulation and controllable sales costs The company will further tap the market potential through the fund-raising project "construction of marketing network system" According to the financial statements of Qianhong pharmaceutical, the gross profit margin of pancreatic kininogenase is stable at more than 70% In a research report in April, Tianxiang Tougu pointed out that the national sales volume of pancreatic kininogenase products is less than 300 million yuan, and Qianhong pharmaceutical occupies more than 60% of the market share It is estimated that by 2015, the national sales of pancreatic kininogenase products will reach 911 million yuan, and Qianhong pharmaceutical will be the biggest beneficiary "Not all the pharmaceutical enterprises involved will be as easy as Qianhong pharmaceutical, especially the products with unified pricing, involving more enterprises, and the gross profit rate of the products is much lower than the products with separate pricing The specific degree of impact of the enterprises will be different due to the different production cost increase of the enterprises But the products with unified pricing are mostly basic drugs, which account for less than 5% of the national drug sales, so the impact of this policy on the entire pharmaceutical industry is limited, "Jiang said The NDRC also said the price adjustment plan was based on the cost price survey According to the head of the national development and Reform Commission, hormones, endocrine and nervous system drugs are widely used and have a long cycle This price adjustment has increased the price reduction of drugs with high daily cost, which can effectively reduce the burden of patients; reduced or not reduced the price of drugs with low daily cost, so as to ensure the production and supply of drugs with relatively low price; properly controlled the price reduction range of innovative drugs such as patents, so as to encourage the research and development of drugs; further reduced and unified priced drugs for drugs with independent pricing Price difference between products to promote fair market competition.